Introduction
CLL, adult leukemia
DISEASE PROGRESSION, CLL, REMISSIONS, PROLIFERATION, CHRONIC LYMPHOCYTIC LEUKEMIA
Chronic lymphocytic leukemia (CLL) accounts for up to 30% of adult leukemia worldwide, making it one -of the most common types of blood malignanciesAnti-apoptotic BCL2 signalling is a key feature of CLL that sustains proliferation and accumulation of mature B-cellsHere, we report the 5-year long-term results from the randomized CLL14 study, with all patients being off-study treatment for at least 4 years, demonstrating deeper remissions and longer PFS after Ven-Obi compared with Clb-Obi. Via transcriptional profiling before start of treatment and at relapse, we demonstrate upregulation of resistance mediators like ABCB1 and increased expression of inflammatory gene sets in patients with detectable MRD at the end of Ven-Obi treatment, suggesting possible mechanisms of resistance and disease progression.